<DOC>
	<DOCNO>NCT01521390</DOCNO>
	<brief_summary>GSK573719 high-affinity specific muscarinic receptor ( mAChR ) antagonist develop treatment chronic obstructive pulmonary disease ( COPD ) . The long duration action GSK573719 , administer via inhalation human support potential use long act bronchodilator.This randomize , double-blind , placebo-controlled , 5 period cross-over study healthy male female volunteer . The study measure lung function single inhaled dos two configuration Novel Dry Powder Inhaler . Key assessment include clinical relevant PD parameter : sGaw , FEV1</brief_summary>
	<brief_title>Assessment Lung Function After Single Inhalations Bronchodilator From 2 Configurations Dry Powder Inhaler .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female 18 65 year age inclusive , time signing informed consent . Healthy male female determine responsible experienced physician , base medical evaluation include [ medical history , physical examination , laboratory test cardiac monitoring ] . A subject clinical significant abnormality laboratory parameter outside reference range population study may include Investigator believe find unlikely introduce additional risk factor interfere study procedure . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . [ Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . ] Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 10 day last dose . Body weight ≥ 50 kg BMI within range 19.0 29.9 kg/m2 ( inclusive ) . Normal spirometry ( FEV1 ≥ 80 % predict , FEV1/FVC ≥ 70 % ) . Response ipratropium bromide define increase sGaw ≥25 % predose baseline 2 h follow 80μg ipratropium bromide ; document increase sGaw ≥25 % predose baseline 2 h follow inhalation 80 μg ipratropium bromide within 3 month screen . AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . No significant abnormality 12lead ECG screening , include QTcF &lt; 450msec . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history ( Pack year = ( cigarette per day smoked/20 ) x number year smoke ) ) Subjects able use Novel DPI satisfactorily Subjects , capable give write informed consent , sign date informed consent form include compliance requirement restriction list consent form . A supine mean heart rate outside range 4090 beat per minute ( BPM ) screening . A supine blood pressure persistently high 140/90 millimetre mercury ( mmHG ) screening . History symptomatic arrhythmia . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : • average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Subject asthma history asthma bronchoconstriction . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Subjects keep due regulatory juridical order institution . Subjects military service .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>